Photo By Eric Brown | Pictured is Raymond Schinazi, PhD, Senior VA Research Career Scientist at Atlanta VA...... read more read more
ATLANTA - Valacyclovir, an oral drug commonly used to control the virus that causes genital herpes, appears to reduce the levels of HIV in persons who do not have genital herpes, according to a study by researchers from the National Institutes of Health, Emory University, Atlanta Veterans Affairs Medical Center, Case Western Reserve University and the Civic Association of Health and Education in Lima, Peru.
The study is the first to show that the drug does not require the presence of herpes simplex virus 2 (HSV-2) to suppress HIV in patients. The research shows that the drug probably reduces HIV levels by interfering with HIV's reproductive machinery.
The study is published online in Clinical Infectious Diseases.
The researchers enrolled 18 HIV-infected persons, none of whom was infected with HSV-2, and treated them for 12 weeks. Half of the subjects took valacyclovir twice a day and the other half received a placebo. After two weeks, the placebo group received valacyclovir and the other group received a placebo. When the subjects took valacyclovir, their blood HIV levels declined significantly.
"This study builds on our earlier published work on the impact of acyclovir on HIV-1. Because of the success of this study, the group plans to conduct larger, randomized trials with the hope that valacylovir can eventually be added to the drug cocktail used to treat HIV," says Raymond F. Schinazi, Ph.D., DSc.
Schinazi, a senior author of the study, and also a senior research career scientist at the Atlanta Veterans Affairs Medical Center first received a VA Merit Award grant in 1983 to study combination chemotherapy and antiviral agents shortly following the discovery of the HIV.
In the years that followed, a molecular compound d4T (Stavudine) was created in collaboration with scientists at Yale University and was one of the first drugs used to treat individuals with HIV and it was tested by Schinazi and his dedicated team at the Atlanta VAMC. Subsequently, in collaboration with Dr. Dennis Liotta at Emory University, Schinazi discovered two of the most popular drugs for HIV (Lamivudine and Emtricitabime) that are part of many of the most widely used cocktails for the treatment of HIV. It is estimated that more than 94 percent of people living with HIV take one of the drugs Schinazi invented.
A study by the same research team in 2008 showed that acyclovir suppresses HIV in laboratory cultures of human tissues that were infected with various kinds of herpes viruses. Valacyclovir, which is structurally similar to acyclovir, is converted to acyclovir in the body and remains in the blood longer.
The first authors of the paper are Raymond F. Schinazi (senior author), Emory University School of Medicine and Veterans Affairs Medical Center in Atlanta; Christophe Vanpouille and Andrea Lisco, both with NICHD. Other authors are Leda Bassit, Robert Kauffman, and; Michael Lederman (senior author) and Benigno Rodriguez of Case Western Reserve University and Case Medical Center and Hospitals; and Jorge Sanchez, of The Civic Association for Health and Education in Lima.
Schinazi is also a Frances Winship Walters Professor of Pediatrics in Emory University School of Medicine and a member of the Emory Center for AIDS Research (CFAR).
The study was supported by Emory's CFAR as well as the NIH's Bench to Bedside Program, which funds research teams seeking to translate basic scientific findings into medical practice.
For more information see the NIH press release.
| Date Taken: | 03.27.2015 |
| Date Posted: | 03.27.2015 15:06 |
| Story ID: | 158372 |
| Location: | ATLANTA, GEORGIA, US |
| Web Views: | 198 |
| Downloads: | 0 |
This work, New study determines herpes drug may help control HIV, must comply with the restrictions shown on https://www.dvidshub.net/about/copyright.
No keywords found.
